P-281 JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line che
An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses
![Breelyn WILKY | Managing Director | University of Colorado, CO | UCD | Department of Medicine | Research profile Breelyn WILKY | Managing Director | University of Colorado, CO | UCD | Department of Medicine | Research profile](https://i1.rgstatic.net/ii/profile.image/788691467390979-1565050107964_Q512/Breelyn-Wilky.jpg)
Breelyn WILKY | Managing Director | University of Colorado, CO | UCD | Department of Medicine | Research profile
![Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™ Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™](https://static.wixstatic.com/media/c22a133631fe4bd097252f75db1e8422.jpg/v1/fill/w_1000,h_732,al_c,q_85,usm_0.66_1.00_0.01/c22a133631fe4bd097252f75db1e8422.jpg)